Successful pseudorabies vaccination in maternally immune piglets using recombinant vaccinia virus vaccines.
Three gilts were vaccinated with a NYVAC vaccinia recombinant expressing glycoprotein gD of pseudorabies virus (PRV) (NYVAC/gD). After farrowing, the piglets were allowed to nurse normally to obtain colostral immunity and then were divided into four groups, receiving NYVAC/gD, a NYVAC recombinant expressing glycoprotein gB of PRV (NYVAC/gB), an inactivated PRV vaccine (iPRV), or no vaccine. The piglets were vaccinated twice, three weeks apart beginning at approximately two weeks of age and later challenged with virulent PRV oronasally. Piglets that received NYVAC/gB or iPRV were the best protected based on lack of mortality, lower temperature responses, decreased weight loss and decreased viral shedding after challenge. These results indicate effective strategies for stimulating active immune response while still under the protection of maternal immunity.
Brockmeier
S I
SI
Virology Swine Research Unit, National Animal Disease Center, USDA, Agricultural Research Service, Ames, Iowa 50010, USA.
Lager
K M
KM
Mengeling
W L
WL
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D011558:Herpesvirus 1, Suid / Q000276:immunology*; D007112:Immunity, Maternally-Acquired / Q000276:immunology*; D015994:Incidence; D011557:Pseudorabies / Q000276:immunology / Q000517:prevention & control*; D013552:Swine; D013553:Swine Diseases / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D013696:Temperature; D014611:Vaccination / Q000379:methods / Q000662:veterinary*; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000032:analysis / Q000276:immunology; D014764:Viral Proteins / Q000032:analysis; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology; D015430:Weight Gain / Q000502:physiology
D000914:Antibodies, Viral; D014614:Vaccines, Synthetic; D014764:Viral Proteins; D014765:Viral Vaccines